Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of “Hold” by Brokerages

Shares of Personalis, Inc. (NASDAQ:PSNL) have been given an average rating of “Hold” by the ten analysts that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $14.5357.

A number of equities research analysts have weighed in on PSNL shares. Wall Street Zen downgraded Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Lake Street Capital downgraded shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price objective for the company. in a research report on Monday, July 20th. Craig Hallum lowered shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price objective for the company. in a research note on Monday, August 24th. BTIG Research boosted their target price on shares of Personalis from $11.00 to $16.25 and gave the company a “buy” rating in a research report on Monday, July 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research note on Friday, July 17th.

Insider Activity

In other news, CEO Christopher Hall sold 100,000 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the transaction, the chief executive officer owned 235,986 shares in the company, valued at approximately $3,558,668.88. This represents a 29.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of the stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18. Following the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at $2,620,618.94. This trade represents a 20.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 256,233 shares of company stock worth $3,568,236 in the last quarter. Company insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Personalis

A number of hedge funds have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd raised its position in shares of Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after purchasing an additional 1,479 shares during the period. International Assets Investment Management LLC acquired a new stake in Personalis in the 4th quarter valued at $31,000. Legal & General Group Plc bought a new stake in Personalis during the 2nd quarter valued at $30,000. Quantbot Technologies LP bought a new stake in Personalis during the 2nd quarter valued at $69,000. Finally, BNP Paribas Financial Markets raised its holdings in Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after buying an additional 5,177 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Stock Performance

Shares of PSNL opened at $17.20 on Wednesday. The stock has a market capitalization of $1.80 billion, a P/E ratio of -15.78 and a beta of 2.31. The firm’s fifty day simple moving average is $14.55 and its two-hundred day simple moving average is $10.30. Personalis has a 12 month low of $4.95 and a 12 month high of $18.89.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The business had revenue of $22.36 million during the quarter, compared to the consensus estimate of $16.69 million. Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. As a group, research analysts predict that Personalis will post -1.07 EPS for the current fiscal year.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.